Skip to content
The Nexus
DossierENTITY

Joe Betts-LaCroix

Coverage of Joe Betts-LaCroix in the Nexus archive.

Earliest in view: May 21 · 18:53 UTCMost recent: May 22 · 11:00 UTC
Co-mentioned in this coverage
Retro Biosciencesorganization2Sam Altmanperson2STAT Breakthrough Summit Westtopic2OpenAIorganization1Alzheimer's diseasetopic1Neil Kumarperson1BridgeBioorganization1The Readout LOUDtopic1
Recent coverage
  • HEALTHMay 22 · 11:00 UTCSTAT NEWS
    STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion

    Retro Biosciences, a longevity startup backed by OpenAI CEO Sam Altman, has raised funding at a $1.8 billion valuation. The company aims to add 10 healthy years to human lifespan through gene therapies and cell replacement therapies. The company is currently running its first clinical trial for an Alzheimer's disease treatment, with positive results and data expected around August.

  • HEALTHMay 21 · 18:53 UTCSTAT NEWS
    Guarding biotech from China and big bets in longevity

    STAT's Breakthrough Summit West brought together leaders in healthcare and science to discuss biotech developments. Key topics included BridgeBio's research publication concerns and Retro Biosciences' progress toward clinical trials, with focus on AI's role in drug development.